Intrinsic value of DarioHealth - DRIO

Previous Close

$0.78

  Intrinsic Value

$0.06

stock screener

  Rating & Target

str. sell

-92%

Previous close

$0.78

 
Intrinsic value

$0.06

 
Up/down potential

-92%

 
Rating

str. sell

We calculate the intrinsic value of DRIO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  8
  13
  19
  28
  39
  54
  72
  95
  122
  154
  191
  234
  282
  335
  394
  459
  529
  603
  683
  768
  858
  953
  1,052
  1,156
  1,264
  1,378
  1,495
  1,618
  1,745
  1,878
Variable operating expenses, $m
  22
  33
  50
  72
  102
  140
  188
  246
  317
  401
  497
  608
  733
  872
  1,026
  1,193
  1,374
  1,569
  1,777
  1,998
  2,231
  2,477
  2,735
  3,005
  3,287
  3,582
  3,888
  4,207
  4,538
  4,883
Fixed operating expenses, $m
  7
  7
  7
  8
  8
  8
  8
  8
  9
  9
  9
  9
  9
  9
  10
  10
  10
  10
  11
  11
  11
  11
  12
  12
  12
  12
  13
  13
  13
  13
Total operating expenses, $m
  29
  40
  57
  80
  110
  148
  196
  254
  326
  410
  506
  617
  742
  881
  1,036
  1,203
  1,384
  1,579
  1,788
  2,009
  2,242
  2,488
  2,747
  3,017
  3,299
  3,594
  3,901
  4,220
  4,551
  4,896
Operating income, $m
  -20
  -28
  -38
  -52
  -70
  -94
  -124
  -160
  -204
  -255
  -315
  -383
  -460
  -546
  -641
  -744
  -856
  -976
  -1,104
  -1,240
  -1,384
  -1,536
  -1,695
  -1,861
  -2,035
  -2,216
  -2,405
  -2,602
  -2,806
  -3,018
EBITDA, $m
  -20
  -27
  -37
  -51
  -69
  -92
  -121
  -157
  -199
  -250
  -308
  -375
  -450
  -534
  -627
  -728
  -837
  -955
  -1,080
  -1,213
  -1,354
  -1,502
  -1,658
  -1,820
  -1,990
  -2,168
  -2,352
  -2,544
  -2,744
  -2,952
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  2
  2
  3
  4
  5
  6
  7
  9
  11
  13
  15
  17
  19
  22
  25
  28
  31
  34
  37
  41
  45
  49
  53
  57
Earnings before tax, $m
  -20
  -28
  -38
  -52
  -71
  -95
  -125
  -162
  -207
  -259
  -320
  -389
  -468
  -555
  -652
  -757
  -871
  -993
  -1,124
  -1,262
  -1,409
  -1,564
  -1,726
  -1,895
  -2,073
  -2,257
  -2,450
  -2,650
  -2,858
  -3,075
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -20
  -28
  -38
  -52
  -71
  -95
  -125
  -162
  -207
  -259
  -320
  -389
  -468
  -555
  -652
  -757
  -871
  -993
  -1,124
  -1,262
  -1,409
  -1,564
  -1,726
  -1,895
  -2,073
  -2,257
  -2,450
  -2,650
  -2,858
  -3,075

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  10
  15
  23
  33
  47
  64
  87
  114
  146
  185
  229
  280
  338
  402
  473
  550
  634
  724
  819
  921
  1,029
  1,142
  1,261
  1,386
  1,516
  1,652
  1,793
  1,940
  2,093
  2,252
Adjusted assets (=assets-cash), $m
  10
  15
  23
  33
  47
  64
  87
  114
  146
  185
  229
  280
  338
  402
  473
  550
  634
  724
  819
  921
  1,029
  1,142
  1,261
  1,386
  1,516
  1,652
  1,793
  1,940
  2,093
  2,252
Revenue / Adjusted assets
  0.800
  0.867
  0.826
  0.848
  0.830
  0.844
  0.828
  0.833
  0.836
  0.832
  0.834
  0.836
  0.834
  0.833
  0.833
  0.835
  0.834
  0.833
  0.834
  0.834
  0.834
  0.835
  0.834
  0.834
  0.834
  0.834
  0.834
  0.834
  0.834
  0.834
Average production assets, $m
  1
  2
  3
  5
  7
  10
  13
  17
  22
  27
  34
  41
  50
  59
  70
  81
  94
  107
  121
  136
  152
  169
  186
  205
  224
  244
  265
  286
  309
  332
Working capital, $m
  -2
  -2
  -4
  -5
  -7
  -10
  -14
  -18
  -23
  -29
  -36
  -44
  -53
  -63
  -75
  -87
  -100
  -114
  -129
  -145
  -162
  -180
  -199
  -218
  -239
  -260
  -283
  -306
  -330
  -355
Total debt, $m
  2
  5
  9
  14
  21
  29
  41
  54
  71
  90
  112
  138
  167
  199
  235
  274
  316
  361
  409
  460
  515
  572
  631
  694
  760
  828
  899
  973
  1,050
  1,130
Total liabilities, $m
  5
  8
  12
  17
  24
  32
  44
  57
  74
  93
  115
  141
  170
  202
  238
  277
  319
  364
  412
  463
  518
  575
  634
  697
  763
  831
  902
  976
  1,053
  1,133
Total equity, $m
  5
  8
  11
  17
  23
  32
  43
  56
  73
  92
  114
  139
  168
  200
  235
  273
  315
  360
  407
  458
  511
  568
  627
  689
  753
  821
  891
  964
  1,040
  1,119
Total liabilities and equity, $m
  10
  16
  23
  34
  47
  64
  87
  113
  147
  185
  229
  280
  338
  402
  473
  550
  634
  724
  819
  921
  1,029
  1,143
  1,261
  1,386
  1,516
  1,652
  1,793
  1,940
  2,093
  2,252
Debt-to-equity ratio
  0.400
  0.620
  0.750
  0.830
  0.880
  0.920
  0.940
  0.960
  0.970
  0.980
  0.990
  0.990
  0.990
  1.000
  1.000
  1.000
  1.000
  1.000
  1.000
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
Adjusted equity ratio
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497
  0.497

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -20
  -28
  -38
  -52
  -71
  -95
  -125
  -162
  -207
  -259
  -320
  -389
  -468
  -555
  -652
  -757
  -871
  -993
  -1,124
  -1,262
  -1,409
  -1,564
  -1,726
  -1,895
  -2,073
  -2,257
  -2,450
  -2,650
  -2,858
  -3,075
Depreciation, amort., depletion, $m
  0
  0
  1
  1
  1
  2
  3
  3
  4
  5
  7
  8
  10
  12
  14
  16
  19
  21
  24
  27
  30
  34
  37
  41
  45
  49
  53
  57
  62
  66
Funds from operations, $m
  -20
  -27
  -38
  -51
  -70
  -93
  -123
  -159
  -202
  -254
  -313
  -381
  -458
  -543
  -638
  -741
  -852
  -972
  -1,099
  -1,235
  -1,379
  -1,530
  -1,688
  -1,854
  -2,028
  -2,209
  -2,397
  -2,593
  -2,797
  -3,008
Change in working capital, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -21
  -22
  -23
  -24
  -25
Cash from operations, $m
  -20
  -27
  -36
  -50
  -68
  -90
  -119
  -155
  -197
  -248
  -306
  -373
  -449
  -533
  -626
  -728
  -839
  -957
  -1,084
  -1,219
  -1,362
  -1,512
  -1,670
  -1,835
  -2,007
  -2,187
  -2,375
  -2,570
  -2,773
  -2,983
Maintenance CAPEX, $m
  0
  0
  0
  -1
  -1
  -1
  -2
  -3
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -14
  -16
  -19
  -21
  -24
  -27
  -30
  -34
  -37
  -41
  -45
  -49
  -53
  -57
  -62
New CAPEX, $m
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -9
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -18
  -19
  -20
  -21
  -22
  -23
  -23
Cash from investing activities, $m
  -1
  -1
  -1
  -3
  -3
  -4
  -5
  -7
  -8
  -10
  -12
  -15
  -17
  -19
  -22
  -25
  -28
  -32
  -35
  -39
  -43
  -47
  -52
  -55
  -60
  -65
  -70
  -75
  -80
  -85
Free cash flow, $m
  -20
  -28
  -38
  -52
  -71
  -94
  -124
  -161
  -205
  -258
  -318
  -387
  -466
  -553
  -649
  -754
  -867
  -989
  -1,120
  -1,258
  -1,405
  -1,559
  -1,721
  -1,890
  -2,067
  -2,252
  -2,444
  -2,644
  -2,852
  -3,069
Issuance/(repayment) of debt, $m
  2
  3
  4
  5
  7
  9
  11
  14
  16
  19
  22
  26
  29
  32
  36
  39
  42
  45
  48
  51
  54
  57
  60
  63
  65
  68
  71
  74
  77
  80
Issuance/(repurchase) of shares, $m
  22
  31
  42
  58
  78
  104
  136
  176
  223
  278
  342
  415
  497
  587
  687
  795
  912
  1,038
  1,171
  1,313
  1,463
  1,620
  1,785
  1,957
  2,137
  2,325
  2,520
  2,723
  2,934
  3,154
Cash from financing (excl. dividends), $m  
  24
  34
  46
  63
  85
  113
  147
  190
  239
  297
  364
  441
  526
  619
  723
  834
  954
  1,083
  1,219
  1,364
  1,517
  1,677
  1,845
  2,020
  2,202
  2,393
  2,591
  2,797
  3,011
  3,234
Total cash flow (excl. dividends), $m
  4
  6
  8
  11
  14
  18
  23
  28
  34
  40
  46
  53
  60
  67
  74
  80
  87
  93
  100
  106
  112
  118
  124
  129
  135
  141
  147
  153
  159
  165
Retained Cash Flow (-), $m
  -22
  -31
  -42
  -58
  -78
  -104
  -136
  -176
  -223
  -278
  -342
  -415
  -497
  -587
  -687
  -795
  -912
  -1,038
  -1,171
  -1,313
  -1,463
  -1,620
  -1,785
  -1,957
  -2,137
  -2,325
  -2,520
  -2,723
  -2,934
  -3,154
Prev. year cash balance distribution, $m
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -17
  -25
  -34
  -47
  -64
  -86
  -113
  -148
  -189
  -238
  -296
  -362
  -437
  -520
  -613
  -715
  -825
  -944
  -1,072
  -1,207
  -1,351
  -1,502
  -1,661
  -1,828
  -2,002
  -2,184
  -2,373
  -2,570
  -2,775
  -2,989
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -17
  -23
  -30
  -39
  -49
  -62
  -77
  -92
  -109
  -125
  -140
  -154
  -166
  -175
  -180
  -182
  -180
  -174
  -165
  -153
  -140
  -125
  -109
  -93
  -78
  -64
  -51
  -40
  -30
  -23
Current shareholders' claim on cash, %
  30.7
  10.7
  4.0
  1.6
  0.7
  0.3
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company's product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter. The Dario product is a digital diabetes management solution utilizing its technology delivered through a software application available for iPhone or Android and cloud-based data services with a blood glucose monitoring system device. Dario allows users to record, analyze, transmit and store various data points, such as glucose level, insulin and carbohydrate intake. It markets the Dario Smart Diabetes Management Solution in the Netherlands and New Zealand.

FINANCIAL RATIOS  of  DarioHealth (DRIO)

Valuation Ratios
P/E Ratio -0.4
Price to Sales 1.5
Price to Book -0.6
Price to Tangible Book
Price to Cash Flow -0.6
Price to Free Cash Flow -0.5
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -244.4%
Ret/ On Assets - 3 Yr. Avg. -263.6%
Return On Total Capital 314.3%
Ret/ On T. Cap. - 3 Yr. Avg. 771.4%
Return On Equity 244.4%
Return On Equity - 3 Yr. Avg. 321.5%
Asset Turnover 0.7
Profitability Ratios
Gross Margin -33.3%
Gross Margin - 3 Yr. Avg. -44.4%
EBITDA Margin -366.7%
EBITDA Margin - 3 Yr. Avg. -355.6%
Operating Margin -366.7%
Oper. Margin - 3 Yr. Avg. -388.9%
Pre-Tax Margin -366.7%
Pre-Tax Margin - 3 Yr. Avg. -355.6%
Net Profit Margin -366.7%
Net Profit Margin - 3 Yr. Avg. -355.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

DRIO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DRIO stock intrinsic value calculation we used $5.17 million for the last fiscal year's total revenue generated by DarioHealth. The default revenue input number comes from 0001 income statement of DarioHealth. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DRIO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DRIO is calculated based on our internal credit rating of DarioHealth, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DarioHealth.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DRIO stock the variable cost ratio is equal to 260%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $7 million in the base year in the intrinsic value calculation for DRIO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for DarioHealth.

Corporate tax rate of 27% is the nominal tax rate for DarioHealth. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DRIO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DRIO are equal to 17.7%.

Life of production assets of 4.5 years is the average useful life of capital assets used in DarioHealth operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DRIO is equal to -18.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $3.941 million for DarioHealth - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 16.744 million for DarioHealth is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DarioHealth at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
DXCM DexCom 135.75 80.46  sell
SENS Senseonics Hol 2.96 0.01  str.sell

COMPANY NEWS

▶ DarioHealth Reports Third Quarter 2018 Results   [Nov-13-18 06:30AM  PR Newswire]
▶ DarioHealth Reports Second Quarter 2018 Results   [Aug-09-18 08:00AM  PR Newswire]
▶ DarioHealth Corp. to Host Earnings Call   [07:00AM  ACCESSWIRE]
▶ DarioHealth Reports First Quarter 2018 Results   [May-15-18 08:00AM  PR Newswire]
▶ DarioHealth Ramps up Commercialization Capabilities   [Apr-30-18 08:00AM  PR Newswire]
▶ DarioHealth Corp. to Host Earnings Call   [07:00AM  ACCESSWIRE]
▶ DarioHealth Partners With a Leading Diabetes Clinic   [Feb-12-18 09:00AM  PR Newswire]
▶ What Can We Expect for DarioHealth Corp (DRIO) Moving Forward?   [Nov-14-17 07:19AM  Simply Wall St.]
▶ DarioHealth Corp. to Host Earnings Call   [06:45AM  ACCESSWIRE]
▶ DarioHealth Corp (DRIO) Scores CE Mark; Shares Soar 36%   [Oct-18-17 03:11PM  SmarterAnalyst]
▶ Should You Sell DarioHealth Corp (DRIO) For This Reason?   [Oct-04-17 11:36AM  Simply Wall St.]
▶ DarioHealth Launches into the German Diabetes Market   [Oct-03-17 08:00AM  PR Newswire]
▶ DarioHealth's MyDario to Appear on The Dr. Oz Show   [Sep-27-17 10:48AM  PR Newswire]
▶ DarioHealth Reports Second Quarter 2017 Results   [Aug-14-17 08:00AM  PR Newswire]
▶ DarioHealth Receives "First Choice" Recognition in the UK   [Jul-10-17 08:01AM  GlobeNewswire]
▶ DarioHealth Reports First Quarter 2017 Results   [May-15-17 07:00AM  PR Newswire]
▶ DarioHealth Lowers Diabetes Healthcare Costs in Canada   [May-04-17 08:00AM  PR Newswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.